The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
本发明提供了 3-(4-(7H-
吡咯并[2,3-d]
嘧啶-4-基)-1H-
吡唑-1-基)-3-环戊基
丙腈的活性代谢物,这些代谢物可调节 Janus 激酶的活性,并可用于治疗与 Janus 激酶活性有关的疾病,例如包括免疫相关疾病、皮肤疾病、骨髓增生性疾病、癌症和其他疾病。